In a pre-specified analysis of the DAPA-CKD trial in patients with FSGS, urine albumin-to-creatinine ratio levels were similar between the dapagliflozin and placebo groups at 12 months; therefore, dedicated multicenter randomized controlled trials of the different forms of FSGS are needed to address the efficacy of SGLT2i in this heterogeneous condition [38]. The gene discussed is ALB; the disease is focal segmental glomerulosclerosis.